| Go ahead for PASSPORT-HF by ethics committee
The ethics committee has evaluated the clinical investigation plan and has provided favourable opinion for the PASSPORT-HF study without further requirements.
- 1
- 2
| First COVID-19 Registry in Rhineland-Palatinate, Germany
Supported by the Ministry of Social Affairs, Labour, Health and Demography of Rhineland-Palatinate, IHF GmbH manages the COVID-19-Registry Rhineland-Palatinate, which was launched this weekend. Registry for Rhineland-Palatinate for the documentation...
| Benefit assessment of an innovative medical device: A study commissioned by the Federal Joint Committee (G-BA)
Commissioned by the Federal Joint Committee (G-BA), IHF GmbH is running one of the first studies on benefit assessment of a medical device in accordance with the directive § 137e Social Security Code Book V (SGB V).
| Advanced methods of case number calculation
Case number planning, which is calculated to match the study design, is an important success factor for precise study results. Our colleague Christiane Lober has studied the methods.
| We say THANK YOU for the good cooperation in 2019.
"Medicine should not only give years to life, but also life to the years." Georg Christoph Lichtenberg
| First milestone in five months
The study protocol has been released and submitted to the Ethics Committee. The first trial phase of PASSPORT-HF is almost completed.
| DGK Herztage from 10.-12. October 2019
IHF GmbH is present at the DGK Herztage in Berlin. You will find us at exhibition stand 4 at the foyer of the Maritim Hotel Berlin.
| Systematically data management
"Scramble of data": This was the title Christiane Lober, statistician at IHF GmbH, used to present the database system she developed at the 23rd SAS Users in Research and Development Conference in Berlin.
| Reboot Paradox
Liebe Patientin, lieber Patient,
hier finden Sie die Kontaktinformationen der an der REBOOT-PARADOX Studie teilnehmenden Kliniken.
Ihr IHF-Studienteam
| REBOOT PARADOX: First Patient in
First patient enrolled in the REBOOT PARADOX clinical trial at Ludwigs-Maximilians-University Munich.
- 1
- 2